Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Musculoskeletal | Rheumatology | Nephrology | Family Medicine
Disease Category: Gout (Hyperuricemia)
Location: United States, MD
A multicenter, randomized, active-controlled , Phase 3B study to evaluate the Cardiovascular safety of Febuxostat (ULORIC) and Allopurinol in subjects with Gout and Cardiovascular Comorbidities
Do you have Gout? You may qualify to participate in a clinical research study.
Cardiovascular Outcomes in gouty arthritis
There are ongoing concerns for the potential of gouty arthritis patients to have a higher risk of adverse cardiovascular events. This trial is seeking gouty arthritis patients with defined cardiovascular events or diabetes who are at high risk for cardiovascular events defined as diabetic patients with microvascular or macrovascular disease. Patients will be randomized to febuxostat (Uloric), in two doses, as well as allopurinol. There will be 5 years of ongoing follow up for enrolled patients.
CW ID: 169940
Date Last Changed:
July 23, 2013
The Center for Rheumatology and Bone Research2730 University Blvd West, Suite 306Wheaton, MD 20902Phone: 301 942-6610Fax: 301 942-7833
The Center for Rheumatology and Bone Research
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.